Comparative Pharmacology
Head-to-head clinical analysis: ABSTRAL versus MORPHABOND ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSTRAL versus MORPHABOND ER.
ABSTRAL vs MORPHABOND ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Morphine is a full opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins. Activation of mu receptors leads to G-protein-coupled inhibition of adenylyl cyclase, decreased cAMP production, closure of voltage-gated calcium channels, and opening of potassium channels. This results in reduced neuronal excitability, inhibition of neurotransmitter release (e.g., substance P, glutamate), and modulation of pain signaling pathways, producing analgesia, euphoria, and sedation.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
15-30 mg orally every 12 hours, titrated to effect; maximum 60 mg per dose or 120 mg daily.
None Documented
None Documented
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is approximately 11–13 hours in adults, allowing once-daily dosing for MORPHABOND ER. In hepatic impairment, half-life may be prolonged.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 90% excreted renally as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), with ~10% excreted unchanged. Fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic